Targeted Therapies Have Improved Survival Among Patients with Metastatic RCC

Share this content:

Overall survival appears to be improving significantly in patients with metastatic renal cell carcinoma (RCC). John Schieszer reports in today's Medical Minute that targeted therapies are making a difference that can be documented.
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters